Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccine Production01:23

Vaccine Production

72
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
72
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.7K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.7K
Development of Immunocompetence01:22

Development of Immunocompetence

1.2K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of bacterial proteins on the host's cell cycle.

Cell cycle (Georgetown, Tex.)·2025
Same author

IFNα induces CCR5 in CD4<sup>+</sup> T cells of HIV patients causing pathogenic elevation.

Communications medicine·2024
Same author

Early elevated IFNα is a key mediator of HIV pathogenesis.

Communications medicine·2024
Same author

Bacterial DnaK reduces the activity of anti-cancer drugs cisplatin and 5FU.

Journal of translational medicine·2024
Same author

Mycoplasma DnaK expression increases cancer development in vivo upon DNA damage.

Proceedings of the National Academy of Sciences of the United States of America·2024
Same author

Mycoplasma DnaK increases DNA copy number variants in vivo.

Proceedings of the National Academy of Sciences of the United States of America·2023
Same journal

NET-inducing ability of Cutibacterium acnes clinical isolates is associated with pathogenicity in acne vulgaris.

The Journal of infectious diseases·2026
Same journal

Optimizing the Use of Proviral DNA HIV Drug Resistance Testing: Clinical Applications and Cautions.

The Journal of infectious diseases·2026
Same journal

Monitoring HLA-A2-restricted T cell responses and BCLA-specific serostatus during human latent Toxoplasma gondii infection suggests the implication of CD8+ T cells in parasite containment.

The Journal of infectious diseases·2026
Same journal

Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).

The Journal of infectious diseases·2026
Same journal

Type 3 fimbrial regulation underpins anti-MrkA immunotherapeutic efficacy in experimental Klebsiella pneumoniae infection.

The Journal of infectious diseases·2026
Same journal

Rationalising heterogeneity in Staphylococcus aureus bacteraemia: current progress and future goals.

The Journal of infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Apr 8, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.9K

Developing a Successful HIV Vaccine.

Robert C Gallo1

  • 1Institute of Human Virology, University of Maryland School of Medicine, Baltimore.

The Journal of Infectious Diseases
|June 28, 2015
PubMed
Summary
This summary is machine-generated.

Developing a human immunodeficiency virus (HIV) vaccine requires persistent sterilizing immunity, necessitating broad antibodies targeting the Env protein. Achieving immune balance is key to overcoming challenges with antibody persistence and vaccine efficacy.

Keywords:
AIDSHIVT cellsantibodiesvaccine

More Related Videos

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

8.1K
Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.8K

Related Experiment Videos

Last Updated: Apr 8, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.9K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

8.1K
Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.8K

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Human immunodeficiency virus (HIV) genome integration necessitates a vaccine inducing persistent sterilizing immunity.
  • Current vaccine strategies focus on broad antibodies targeting the HIV Env protein, particularly gp120.
  • Previous trials like RV144 showed limited, short-lived protection, highlighting challenges in antibody persistence.

Purpose of the Study:

  • To explore the requirements for a successful HIV vaccine candidate.
  • To investigate strategies for inducing persistent, effective antibody responses against HIV.
  • To understand the factors limiting vaccine efficacy, such as immune balance.

Main Methods:

  • Development of immunogens targeting the HIV gp120 protein.
  • Evaluation of immunogen efficacy in blocking infection in animal models.
  • Analysis of antibody-dependent cell-mediated cytotoxicity (ADCC)-like antibodies and their correlation with protection.

Main Results:

  • Immunogens targeting gp120 demonstrated infection blocking in monkeys.
  • Protection observed was short-lived, mirroring the RV144 trial's modest success.
  • Declining ADCC-like antibodies correlated with waning protection.
  • Attempts to enhance antibody persistence were complicated by reduced vaccine efficacy, potentially due to increased HIV-target cells.

Conclusions:

  • Persistent sterilizing immunity is crucial for an effective HIV vaccine.
  • Broadly neutralizing antibodies targeting Env are essential.
  • Achieving a stable immune balance is critical for sustained vaccine efficacy and overcoming challenges in antibody persistence.